Skip to main content
SpringerLink
Log in

Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs

  • Original Paper
  • Published:
European Archives of Psychiatry and Clinical Neuroscience Aims and scope Submit manuscript

Abstract

We evaluated the effects of mianserin, a relatively selective 5-HT2 receptor antagonist, on symptoms related to drug-induced psychosis in patients with Parkinson's disease (PD). A total of 12 patients with PD who had developed drug-induced psychosis showed delirium (DSM-III-R criteria;n=10) and pure visual hallucinations (n=2). The antiparkinsonian drugs involved in the drug-induced psychosis werel-DOPA/carbidopa, bromocriptine, trihexyphenidyl, and amantadine. They received mainserin (mean 36.7 mg, range 20–60 mg) given orally for 8 weeks. Complete relief or marked improvement in psychotic symptoms was noted in 8 patients, moderate improvement in 2 patients, and no effect in 2 patients. The parkinsonian disability also decreased slightly in 8 patients. These results suggest that serotonin antagonism at 5-HT2 receptors may not only play an important role in the treatment of drug-induced psychosis in PD, but may also ameliorate the symptoms of parkinsonism.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • American Psychiatric Association (1980) Diagnostic and statistical manual of mental disorders (DSM-III). American Psychiatric Association; Washington, DC

    Google Scholar 

  • American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders (DSM-III-R), 3rd edn, revised. American Psychiatric Association, Washington, DC

    Google Scholar 

  • Baldessarini RJ (1990) Drugs and the treatment of psychiatric disorders. In: Gilman AG, Rall TW, Nies AS, Taylor P (eds) Goodman and Gilman's the pharmacological basis of therapeutics, Pergamon Press, New York, pp 383–435

    Google Scholar 

  • Beasley BL, Nutt JG, Davenport RW, Chase TN (1980) Treatment with tryptophan of levodopa-associated psychiatric disturbances. Arch Neurol 37:155–156

    Google Scholar 

  • Bersani G, Grispini A, Marini S, Pasini A, Valducci M, Ciani N (1986) Neuroleptic-induced extrapyramidal side effects: clinical perspectives with ritanserin (R 55667), a new selective 5-HT2 receptor blocking agent. Curr Ther Res 40:492–499

    Google Scholar 

  • Birkmayer W (1978) Toxic delirium afterl-dopa medication. J Neural Transm (Suppl) 14:163–166

    Google Scholar 

  • Blackwell B (1984) Antidepressant drugs. In: Dukes MNG (ed) Meyler's side effects of drugs, 10th edn. Excerpta Medica, Amsterdam, pp 24–61

    Google Scholar 

  • Bouchard RH, Pourchur E, Vincent P (1989) Fluoxetine and extrapyramidal side effects. Am J Psychiatry 146:1352–1353

    Google Scholar 

  • Brogden RN, Heel RC, Speight TM, Avery GS (1978) Mianserin: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs 16:273–301

    Google Scholar 

  • Celesia GG, Barr AN (1970) Psychosis and other psychiatric manifestatitions of levodopa therapy. Arch Neurol 23:193–200

    Google Scholar 

  • Chase TN (1970) 5-Hydroxytryptophan in parkinsonism. Lancet 2: 1029–1030

    Google Scholar 

  • Chase TN, Ng LKY, Watanabe AM (1972) Parkinson's disease. Modification by 5-hydroxytryptophan Neurology 22:479–484

    Google Scholar 

  • Declerck AC, Wauquier A, Van Der Ham-Veltman, Gelders Y (1987) Increase in slow-wave sleep in humans with the serotonin-S2 antagonist ritanserin. Curr Ther Res 41:427–432

    Google Scholar 

  • De Smet Y, Ruberg M, Serdaru M, Dubois B, Lhermitte F, Agid Y (1982) Confusion, dementia and anticholinergics in Parkinson's disease. J Neurol Neurosurg Psychiatry 45:1161–1164

    Google Scholar 

  • Duinkerke SJ, Botter PA, Jansen AAI, Van Dongen PAM, Van Haaften AJ, Boom AJ, Van Laarhoven JH, Busard HLSM (1993) Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled doubleblind trial. Br J Psychiatry 163:451–455

    Google Scholar 

  • Fahn S, Elton RL, UPDRS Development Committee (1987) United Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Recent developments in Parkinson's disease. McMillian Health Information, Florham Park, New York, pp 153–163

    Google Scholar 

  • Fitton A, Heel RC (1990) Clozapine: a review of its pharmacological properties and therapeutic use in schizophrenia. Drugs 40: 722–747

    Google Scholar 

  • Gehlen W, Müller J (1974) Zur Therapie der Dopa-Psychosen mitl-Tryptophan. Dtsch Med Wochenschr 99:457–463

    Google Scholar 

  • Gelders Y, YandenBusshe G, Reyntjens A, Janssen P (1986) Serotonin-S2 receptor blockers in treatment of chronic schizophrenia. Clin Neuropharmacol 9:325–327

    Google Scholar 

  • Glenonn RA, Young R, Rosecrans JA (1983) Antagonism of the effects of the hallucinogen DOM and the purported 5-HT agonist quipazine by 5-HT2 antagonists. Eur J Pahrmacol 91:189–196

    Google Scholar 

  • Glennon RA, Titeler M, McKenney JD (1984) Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 35:2505–2511

    Google Scholar 

  • Gottfries CG, Bråne G, Steen G (1982) A new rating scale for dementia syndromes. Gerontology 28 (Suppl 2):20–31

    Google Scholar 

  • Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427–442

    Google Scholar 

  • Idzikowski C, Mills FJ, Glennard R (1986) 5-Hydroxytryptamine-2 antagonist increases human slow-wave sleep. Brain Res 378: 146–148

    Google Scholar 

  • Korsgaard S, Friis T (1986) Effects of mianserin in neuroleptic-induced parkinsonism. Psychopharmacology 88:101–111

    Google Scholar 

  • Lehmann J (1973) Tryptophan malabsorption in levodopa-treated parkinsonian patients. Effects of tryptophan on mental disturbances. Acta Med Scand 194:181–189

    Google Scholar 

  • Lukoff D, Neuchterlein KH, Ventura J (1986) Manual for expanded brief psychiatric rating scale (BPRS). Schizophr Bull 12:594–602

    Google Scholar 

  • Meltzer HY, Nash JF (1991) Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 43:587–604

    Google Scholar 

  • Narabayashi H, Kondo T, Hayashi A, Suzuki T, Nagatsu T (1981)l-threo-3,4-dihydroxyphenylserine treatment for akinesia and freezing of parkinsonism. Proc Jpn Acad 57(B):351–354

    Google Scholar 

  • Paiva T, Arriaga F, Wauquier A (1988) Effects of ritanserin on sleep disturbances of dysthymic patients. Psychopharmacology 96:395–399

    Google Scholar 

  • Peroutka SJ (1987) Serotonin receptors. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 303–311

    Google Scholar 

  • Schmidt MJ, Fuller RW, Wong DT (1988) Fluoxetine, a highly selective serotonin reuptake inhibitor: a review of preclinical studies. Br J Psychiatry 153 (Suppl 3):40–46

    Google Scholar 

  • Scholz E, Dichgans J (1985) Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur Arch Psychiatry Neurol Sci 235:60–64

    Google Scholar 

  • Schuster P, Gabriel E, Kufferle B, Stobl G, Karobath M (1977) Reversal by physostigmine of clozapine-induced delirium. Clin Toxicol 10:437–441

    Google Scholar 

  • Steur EN (1993) Increase of Parkinson disability after fluoxetine medication. Neurology 43:211–213

    Google Scholar 

  • Tate JL (1989) Extrapyramidal symptoms in a patient taking haloperiodol and fluoxetine. Am J Psychiatry 146:399–400

    Google Scholar 

  • Trepacz PT, Baker RW, Greenhouse J (1988) A symptom rating scale for delirium. Psychiatry Res 23:89–97

    Google Scholar 

  • Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, Civelli O (1991) Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350:610–614

    Google Scholar 

  • Wolters EC, Hurwitz TA, Mak E, Teal P, Peppard FR, Remick R, Calne S, Calne DB (1990) Clozapine in the treatment of parkinsonian patients with dopaminergic psychosis. Neurology 40:832–834

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Jichi Medical School, 329-04, Minamikawachi Tochigiken, Japan

    K. Ikeguchi

  2. Department of Psychiatry, Tokyo Metropolitan Matsuzawa Hospital, Kamikitazawa 2-1-1, Setagaya, 156, Tokyo, Japan

    A. Kuroda

Authors
  1. K. Ikeguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Kuroda
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ikeguchi, K., Kuroda, A. Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs. Eur Arch Psychiatry Clin Nuerosci 244, 320–324 (1995). https://doi.org/10.1007/BF02190411

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02190411

Key words

Search

Navigation